东方生物
(688298)
| 流通市值：55.96亿 | | | 总市值：55.96亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 652,171,856.12 | 501,543,883.09 | 376,045,281.02 | 8,767,938,106.37 |
| 营业收入 | 652,171,856.12 | 501,543,883.09 | 376,045,281.02 | 8,767,938,106.37 |
| 二、营业总成本 | 718,719,790.87 | 457,566,614.1 | 424,274,588.63 | 5,068,042,781.38 |
| 营业成本 | 409,985,623.8 | 323,663,206.57 | 252,959,590.96 | 4,314,399,061.18 |
| 税金及附加 | 5,644,353.55 | 3,554,230.4 | 2,921,588.49 | 89,545,810.23 |
| 销售费用 | 117,077,775.48 | 76,264,247.95 | 40,212,550.96 | 485,112,510.93 |
| 管理费用 | 249,985,608.25 | 157,735,102.42 | 77,212,870.66 | 270,692,735.93 |
| 研发费用 | 188,135,533.21 | 123,739,625.87 | 51,904,828.32 | 511,564,379.22 |
| 财务费用 | -252,109,103.42 | -227,389,799.11 | -936,840.76 | -603,271,716.11 |
| 其中:利息费用 | 11,726,511.09 | 6,054,663.37 | 2,858,409.85 | 6,966,960.3 |
| 其中:利息收入 | 158,298,097.02 | 101,118,115.34 | 42,722,908.92 | 116,842,993.93 |
| 加:公允价值变动收益 | -929,534.18 | -929,534.18 | -929,534.18 | 1,660,263.64 |
| 加:投资收益 | 30,382,391.48 | 21,401,847.77 | 10,621,780.63 | 6,023,463.65 |
| 资产处置收益 | -162,882.94 | 94,231.78 | 142,311.32 | -7,951.4 |
| 资产减值损失(新) | -16,071,100.49 | -9,061,566.3 | 37,627,630.24 | -1,209,740,035.08 |
| 信用减值损失(新) | 425,768.97 | -224,963.37 | -1,121,786.65 | 5,819,385.58 |
| 其他收益 | 8,465,436.48 | 5,473,940.88 | 443,217.23 | 24,559,648.92 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -44,437,855.43 | 60,731,225.57 | -1,445,689.02 | 2,528,210,100.3 |
| 加:营业外收入 | 4,259,386.07 | 4,211,753.76 | 664,966.17 | 319,203.23 |
| 减:营业外支出 | 6,061,549.84 | 5,726,327.51 | 36,874,313.46 | 57,776,938.71 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -46,240,019.2 | 59,216,651.82 | -37,655,036.31 | 2,470,752,364.82 |
| 减:所得税费用 | 21,026,339.99 | 21,270,322.95 | 8,757,840.69 | 373,321,128.04 |
| 六、净利润 | -67,266,359.19 | 37,946,328.87 | -46,412,877 | 2,097,431,236.78 |
| 持续经营净利润 | -67,266,359.19 | 37,946,328.87 | -46,412,877 | 2,097,431,236.78 |
| 归属于母公司股东的净利润 | -72,383,980.73 | 34,807,586.49 | -50,330,075.15 | 2,067,714,327.6 |
| 少数股东损益 | 5,117,621.54 | 3,138,742.38 | 3,917,198.15 | 29,716,909.18 |
| (一)基本每股收益 | -0.36 | 0.17 | -0.3 | 12.31 |
| (二)稀释每股收益 | -0.36 | 0.17 | -0.3 | 12.31 |
| 八、其他综合收益 | 24,878,026.66 | 28,919,674.68 | -13,260,781.25 | 40,989,801.51 |
| 归属于母公司股东的其他综合收益 | 24,878,026.66 | 28,919,674.68 | -13,260,781.25 | 40,989,801.51 |
| 九、综合收益总额 | -42,388,332.53 | 66,866,003.55 | -59,673,658.25 | 2,138,421,038.29 |
| 归属于母公司股东的综合收益总额 | -47,505,954.07 | 63,727,261.17 | -63,590,856.4 | 2,108,704,129.11 |
| 归属于少数股东的综合收益总额 | 5,117,621.54 | 3,138,742.38 | 3,917,198.15 | 29,716,909.18 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-28 | 2023-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |